LabCorp Venture Fund, Bristol Myers Squibb and Takeda Ventures contributed to $7m in equity funding and a $6m convertible note for the cancer drug developer.
Israel-based oncology drug developer Presage Biosciences has raised $13m from investors including research services provider LabCorp and pharmaceutical firms Takeda and Bristol Myers Squibb.
New investors including LabCorp’s Venture Fund, Bristol Myers Squibb and venture capital and private equity firm InHarv Partners supplied $7m in equity funding while Takeda provided $6m in convertible note financing through subsidiary Takeda Ventures.
Presage is developing cancer therapeutics based on its intratumoral microdosing technology, and disclosed the financing alongside research partnerships with pharmaceutical companies…
